---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-027582"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:13:57.362038+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# EyePoint reports Q4/FY2023 results; positive Phase 2 data for EYP-1901 in wet AMD

## Summary
- Q4 net loss $14.1M ($0.33/sh) vs $43.5M ($1.16/sh) YoY; total net revenue $14.0M (+33%).
- Cash and investments $331M as of Dec 31, 2023, funding operations through Phase 3 topline data for wet AMD in 2026.
- Positive Phase 2 DAVIO 2 data: EYP-1901 met all primary/secondary endpoints; first Phase 3 trial expected 2H 2024.
- First patient dosed in Phase 2 VERONA trial for DME; topline data 1Q 2025; PAVIA NPDR data expected 2Q 2024.
- Appointed Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer.

## SEC filing metadata
- accession: 0000950170-24-027582
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017024027582/0000950170-24-027582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017024027582/eypt-20240307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-027582
- JSON: https://secwatch.observer/filing/0000950170-24-027582.json
- Plain text: https://secwatch.observer/filing/0000950170-24-027582.txt

## Key facts
- Earnings Releases
  EyePoint, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: On March 7, 2024, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023 and certain other information.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1314102/000095017024027582/0000950170-24-027582-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.